Managing HER2 Positive and Negative Disease in the Metastatic Setting: Bringing Clarity to the Confusion

Breast cancer represents a heterogeneous array of different disease subtypes that have unique molecular phenotypes and distinct clinical features. Despite advances in the treatment of early-stage breast cancer, approximately one third of patients will eventually develop metastatic breast cancer (MBC). The increased understanding of the biology of breast cancer has led to the classification of tumors based upon their molecular features and the development and use of targeted therapies for the treatment of both early and metastatic cancer. Targeted agents and their promise of better patient outcomes with respect to safety, survival, and quality of life may change the clinical course for many MBC patients.

Available until February 7, 2012, this activity offers:
Physicians: 1.25 AMA PRA Category 1 Credits^™
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: 1.4 contact hours

This CME/CE activity is jointly sponsored by Postgraduate Institute for Medicine and CME Incite.

 

[Back to top]

[Back to Activity Home]